Get the Stockscreener App
144.48
1.18%
1.69
After Hours:
144.68
0.20
+0.14%
Insmed Inc stock is traded at $144.48, with a volume of 2.05M.
It is up +1.18% in the last 24 hours and up +0.38% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$142.79
Open:
$144.25
24h Volume:
2.05M
Relative Volume:
0.85
Market Cap:
$31.19B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-22.56
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
-6.67%
1M Performance:
+0.38%
6M Performance:
-12.84%
1Y Performance:
+98.87%
1-Day Range:
$143.28
$145.62
1-Week Range:
$142.03
$156.64
52-Week Range:
$63.81
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
144.48 | 31.19B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
INSM Reiterates by Roth Capital -- Price Target Maintained at $2 - GuruFocus
Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - 富途牛牛
William Lewis lists INSM share sales (NASDAQ: INSM) in Form 144 filing - Stock Titan
Guggenheim raises Insmed stock price target to $230 on Arikayce By Investing.com - Investing.com Canada
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Insmed, Inc. (NASDAQ:INSM) Short Interest Update - MarketBeat
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Insmed Inc stock (US4576693075): Is brensocatib approval the real test for rare disease growth? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Purchases Shares of 435,442 Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Raised to $216 - GuruFocus
Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says - Moomoo
Oak Ridge Investments LLC Trims Position in Insmed, Inc. $INSM - MarketBeat
RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating - marketscreener.com
RBC Capital Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $216 - Moomoo
RBC Capital raises Insmed stock price target on Brinsupri outlook By Investing.com - Investing.com Canada
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
EBIT per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Institution Moves: What are the future prospects of Insmed Incorporated2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
US Stocks Recap: Is URTY a cyclical or defensive stockGap Up & Verified Swing Trading Watchlist - baoquankhu1.vn
Risk Analysis: Is Insmed Incorporated stock a buy or sell2026 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Insmed (INSM): Top QQQ Stock to Buy Now - Yahoo Finance
Insmed Achieves $280 Million Trading Volume, Secures Leading Market Position Despite Positive Analyst Ratings and Clinical Challenges - Bitget
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More - 24/7 Wall St.
What is HC Wainwright's Estimate for Insmed FY2027 Earnings? - MarketBeat
Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge? - Yahoo Finance
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
FRANKLIN GROWTH OPPORTUNITIES FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Halts Brensocatib R&D After Trial Setback - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock - Investing.com
Insmed chair and CEO William Lewis sells $1.75 million in stock By Investing.com - Investing.com South Africa
Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing - Moomoo
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
Trial Failure in the Skin Does Not Dent Insmed Drug’s Potential in the Lungs - MedCity News
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake - Yahoo Finance
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure - Yahoo Finance
Insmed Drug Misses Primary Goal, Program Axed - Benzinga
Insmed freezes Brinsupri’s HS programme on Phase II failure - Yahoo Finance
Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating - marketscreener.com
Insmed drops skin disorder candidate after mid-stage trial setback - Seeking Alpha
Insmed drops HS program for Brinsupri after Phase IIb miss - The Pharma Letter
Insmed stock falls after failed hidradenitis suppurativa trial By Investing.com - Investing.com South Africa
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Fails to Meet Endpoints - Minichart
AVIP AB Mid Cap Core Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed (INSM) Maintains Buy Rating Despite Trial Setback - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Apr 16 '26 |
Sale |
143.97 |
10,699 |
1,540,332 |
301,185 |
0.43%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):